Linezolid for the treatment of infections a review of the clinical and cost-effectiveness
The purpose of this report is to examine the comparative clinical effectiveness of linezolid, vancomycin and daptomycin for Methicillin-resistant Staphylococcus aureus (MRSA) infections, the comparative clinical effectiveness of linezolid and daptomycin for the treatment of VRE infections, and the c...
| Main Authors: | , , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
CADTH
October 25, 2017, 2017
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: peer review with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The purpose of this report is to examine the comparative clinical effectiveness of linezolid, vancomycin and daptomycin for Methicillin-resistant Staphylococcus aureus (MRSA) infections, the comparative clinical effectiveness of linezolid and daptomycin for the treatment of VRE infections, and the cost-effectiveness of linezolid and daptomycin for MRSA and vancomycin-resistant enterococci (VRE) infections. Additionally, the clinical effectiveness and cost-effectiveness of oral versus intravenous linezolid will be examined |
|---|---|
| Physical Description: | 1 PDF file (60 pages) illustration |